18F-RD2

18F-RD2 is a radiolabeled D-enantiomeric peptide (D-peptide) designed as a positron emission tomography (PET) tracer for the selective imaging of toxic amyloid-beta (Aβ) oligomers in the brain. Developed by researchers at Forschungszentrum Jülich and its spin-off Priavoid, it is derived from the therapeutic drug candidate RD2 (PRI-001). Unlike conventional amyloid PET tracers such as florbetapir or PiB, which primarily bind to insoluble fibrillar amyloid plaques, 18F-RD2 is engineered to specifically target soluble Aβ oligomers, which are widely considered the most neurotoxic species and early drivers of Alzheimer's disease pathology. The D-peptide structure of the tracer provides high stability against proteolytic degradation in vivo. 18F-RD2 serves as a diagnostic tool for early detection of Alzheimer's disease and as a companion diagnostic to monitor the target engagement and efficacy of anti-oligomer therapeutic interventions.

Other names

18F-labeled RD2Fluorine-18 labeled RD2Fluorine18 labeled RD2Fluorine 18 labeled RD2RD2-PETRD-2-PETRD 2-PET